DNMT3A and myeloid neoplasm: Given that DNMT3A mutations often occurred early in the development of myeloid neoplasm and rarely acquired during disease progression (31–34), this result suggests that CHIP harboring R882 mutations has a higher risk of developing AML than non-R882 mutations (about 5-fold).